Cel­lec­tis shifts CAR-T man­u­fac­tur­ing in-house, boosts ef­fi­ca­cy com­pared to third-par­ty CD­MOs: #ASH23 

Al­lo­gene­ic CAR-T biotech Cel­lec­tis took its CAR-T man­u­fac­tur­ing in-house af­ter fac­ing “bro­ken” sup­ply chain is­sues with third par­ty man­u­fac­tur­ers, and, ac­cord­ing to the com­pa­ny, the move boost­ed its ef­fi­ca­cy da­ta and ac­cel­er­at­ed its pro­duc­tion.

“It’s a strate­gic move; it’s not just fix­ing a bro­ken sup­ply chain. It’s al­so get­ting ready for what’s go­ing to make a big dif­fer­ence for us,” said David Sour­dive, Cel­lec­tis EVP of CMC and man­u­fac­tur­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER